Blockchain Registration Transaction Record

Oncotelic Therapeutics Opens Enrollment for STOP-PC Clinical Trial

Alarming increase in early-onset pancreatic cancer rates prompts Oncotelic Therapeutics to open enrollment for STOP-PC clinical trial. Potential breakthrough in pancreatic cancer treatment.

The rise in early-onset pancreatic cancer rates is a concerning trend that affects not only patients but also the healthcare industry and society as a whole. The efforts of Oncotelic Therapeutics to develop more therapeutic options for pancreatic cancer could potentially improve survival rates and quality of life for patients facing this deadly disease. The STOP-PC clinical trial holds the potential to significantly impact the future treatment of pancreatic cancer.